BI-1808 +/- KEYTRUDA

26 Aug 2025 — BioInvent International AB (Nasdaq Stockholm: BINV) announced a strategic portfolio optimization to concentrate resources on its lead immuno-oncology antibodies BI-1808 (first-in-class anti-TNFR2; Phase 2a in solid tumors and cutaneous T-cell lymphoma) and BI-1206 (FcγRIIB-blocking antibody; Phase 2a in non-Hodgkin’s lymphoma), aiming to accelerate clinical milestones and strengthen paths toward regulatory approval. A Phase 2a study of BI-1206 combined with pembrolizumab in first-line metastatic NSCLC is planned to start in H2 2025.

BioInvent will pause Phase 1 programs BI-1910 and BI-1607, and continue BT-001 development via an investigator-led trial with Transgene. Subject to union negotiations, BioInvent plans a workforce reduction of ~25 positions and expects cash runway into Q1 2027.

Key upcoming catalysts: H2 2025 Phase 2a data for BI-1808 + pembrolizumab in solid tumors; H1 2026 additional BI-1206 triplet data in NHL and BI-1808 data in CTCL; H2 2026 first readout from BI-1206 + pembrolizumab Phase 2a in treatment-naïve NSCLC and uveal melanoma.